Please login to the form below
siltuximab
This page shows the latest siltuximab news and features for those working in and with pharma, biotech and healthcare.
EC approves Janssen rare blood disorder drug
Sylvant (siltuximab) offers a more promising alternative, however, and has demonstrated in clinical trials it can reduce the size of tumours and stabilise disease symptoms, such as fever. ... Not every MCD patient will be eligible for treatment with
Latest news
-
FDA approves Janssen drug for rare Castleman’s disease
Sylvant (siltuximab), marketed by Johnson &Johnson subsidiary Janssen Biotech, is the first drug backed by the FDA to treat multicentric Castleman's disease, which the agency describes as a rare disorder
-
J&J files rare blood disorder drug siltuximab in US and EU
Johnson &Johnson (J&J) has filed for approval of its investigational drug siltuximab in both the EU and US as a treatment for a rare blood disorder. ... The submissions are based primarily on data from the randomised MCD2001 study, which compared
-
J&J positive about pipeline
Also on the list are fulranumab for osteoarthritis pain; siltuximab for castleman's disease, a rare disorder that is similar to lymphoma; TMC-207 for MDR tuberculosis; TMC 435 for hepatitis
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Content Editor - Biotechnology
-
Salary TBC
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
-
Principal Medical Writer
-
Varies on experience
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- CureVac expands COVID-19 vaccine trial protocol to include variant specification
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement
- Lucid Group Bolster its Senior Leadership Team
- Live Webinar: Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Opdivo improves survival in oesophageal cancer
- Keytruda shows significant and meaningfully improvement in kidney cancer
- Congress 2020 BC (before COVID-19)
- Shaping the Future of Medicine, Science, and Technology
- Live Webinar: Virtual Trials, Remote Care, & Cross-Border Collaboration: Ethical & Legal Challenges
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Virtual congresses: video thrilled the cardio tsar
- Chris Ross explores the key learnings from a year of virtual congresses...
- When Will We Be Back To Normal?
- The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
- How to tell your healthcare story.
- Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....
Quick links
Infographics
